Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

BelgiumBack to Belgium

Clinical trials in Jette – page 3

260 clinical trials in Jette, Belgium across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Jette at a glance
260
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

260 trials in Jette

Open in trial search

Breast cancer metastatic

Recruiting

A study of palazestrant and ribociclib compared to letrozole and ribociclib for patients with advanced ER+ HER2- breast cancer

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Letrozole
  • Sponsor:Olema Pharmaceuticals Inc.

Acute myeloid leukaemia

Recruiting

Study of ziftomenib with drug combinations for adults with newly diagnosed acute myeloid leukemia with NPM1 or KMT2A genetic changes

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Kura Oncology Inc.

Metabolic dysfunction-associated liver disease

Recruiting

N1T-MC-MALO: A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Who Are at Increased Risk of Developing Major Adverse Liver Outcomes (SYNERGY-Outcomes); N1T-MC-TZ01 Tirzepatide in participants with high-risk MASLD; N1T-MC-RT01 Retatrutide in participants with high-risk MASLD

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:LY3437943 sodium
  • Sponsor:Eli Lilly & Co.

Interstitial lung disease

Recruiting

Efficacy and Safety of Subcutaneous Belimumab in Adults with Connective Tissue Disease-Associated Interstitial Lung Disease

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Belimumab
  • Sponsor:Glaxosmithkline Research & Development Limited

Acute kidney injury

Recruiting

A study testing how well AZD4144 works and how safe it is for adults with acute kidney injury caused by sepsis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Sponsor:AstraZeneca AB

A study comparing macrogol 3350 combination and sodium picosulfate for bowel cleansing before colonoscopy in children and teenagers with colonic disease

Recruiting
Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Ascorbic Acid
  • Sponsor:Norgine Limited

Cardiac amyloidosis

Recruiting

A study of coramitug compared to placebo for people with heart failure caused by transthyretin amyloid cardiomyopathy

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Coramitug
  • Sponsor:Novo Nordisk A/S

A Study of SAB-142 to Slow the Progression of Type 1 Diabetes in Adults and Children Recently Diagnosed with the Disease

Recruiting
Registered drug
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Sodium Chloride
  • Sponsor:Sab Biotherapeutics Inc.

Colitis ulcerative

Recruiting

Testing icotrokinra compared to placebo for adults and adolescents with moderately to severely active ulcerative colitis

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Icotrokinra
  • Sponsor:Janssen Cilag International

Abortion spontaneous

Recruiting

Comparing hysteroscopic surgery to mifepristone and misoprostol treatment for early pregnancy loss in women under 10 weeks of pregnancy

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Mifepristone
  • Sponsor:UZ Brussel

Diabetes mellitus

Recruiting

A Study of Teplizumab Compared to Placebo for Blood Sugar Control in Children and Young Adults Aged 1 to 25 Years with Newly Diagnosed Type 1 Diabetes

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Teplizumab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Breast cancer+2

Recruiting

A Study Comparing RLY-2608 and Fulvestrant with Capivasertib and Fulvestrant for Patients with PIK3CA-Mutant Hormone Receptor Positive, HER2-Negative Advanced Breast Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Capivasertib
  • Sponsor:Relay Therapeutics Inc.

Other cities in Belgium

The busiest research cities in the country

All 170 cities in Belgium

Clinical research in Jette

What the registry says about research in the country

01 Oncology Research

Clinical investigations focusing on innovative treatments for various cancers, including non-small cell lung cancer, melanoma, and colorectal cancer. Studies are evaluating new combination therapies and targeted treatments to improve patient outcomes.

  • Lung cancer therapeutics
  • Melanoma treatments
  • Pediatric liver tumors

Advanced clinical trials exploring immunotherapy combinations and targeted molecular approaches.

02 Metabolic Disorders

Research focusing on treatments for diabetes and obesity, including innovative therapies for both Type 1 and Type 2 diabetes. Studies are evaluating new medications for weight management and metabolic control.

  • Type 1 diabetes interventions
  • Obesity management
  • Weight maintenance in adolescents

Comprehensive trials investigating metabolic disease management and treatment outcomes.

03 Neurological Conditions

Studies examining treatments for status epilepticus and Alzheimer's-related psychosis. Research includes innovative approaches to managing neurological complications following cardiac arrest.

  • Post-cardiac arrest care
  • Alzheimer's disease complications
  • Seizure management

Advanced clinical research focusing on improving neurological outcomes and patient care.

Back to BelgiumAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.